EVIDENCE LIBRARY
Darolutamide Study Showed That a Large Statin Interaction Did Not Predict an Equally Large Midazolam Effect
A drug-interaction program examined enzymes and transporters with different probes. Its strongest clinical exposure change involved a transporter substrate, not every tested medicine.
A drug-interaction program examined enzymes and transporters with different probes. Its strongest clinical exposure change involved a transporter substrate, not every tested medicine.
The distinct probe results
The program combined laboratory assays with phase-one studies. Darolutamide had no effect or only minor effects on tested CYP3A4 and P-glycoprotein substrates, including midazolam in the CYP3A assessment.
Rosuvastatin exposure increased much more substantially, consistent with transporter inhibition. Separate studies assessed medicines that changed darolutamide exposure itself.
Direction and pathway matter
A medicine can be a victim of one interaction and the cause of another. A transporter finding should not be transferred automatically to a CYP3A probe.
The study cannot establish a fivefold midazolam increase simply because a statin increased by that magnitude. Nor does it establish absence of all interactions in patients with multiple co-medications. Forensic interpretation should specify the interacting pair, direction, regimen, and pathway rather than applying a single interaction label to an entire treatment list.
Source paper
Original analysis of the supplied journal article, identified as PMC6828636.